Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00982111 · ClinicalTrials.gov registry record · Phase 3
First-line Treatment of Patients With Stage IV Nonsquamous Non-Small Cell Lung Cancer With Necitumumab (IMC-11F8) and Pemetrexed-Cisplatin
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 633
- Enrollment target
NCT00982111 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 633 participants.
The verdict
NCT00982111, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 633 participants
- Enrollment target
Study Summary
The research study is testing the investigational drug necitumumab in the treatment of advanced non-small cell lung cancer. The aim of this study is to determine if necitumumab, given together with a standard chemotherapy combination consisting of cisplatin and pemetrexed will be more effective in improving participant disease than the standard chemotherapy combination alone.
Interventions
- DRUG Cisplatin
- DRUG Pemetrexed
- BIOLOGICAL Necitumumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 633 participants |
| Start Date | 2009-11-02 |
| Est. Completion | 2020-12-23 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00982111
The ClinicalTrials.gov registry entry for NCT00982111 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 633 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cisplatin is the first listed.
NCT00982111 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00982111 about?
NCT00982111 is a clinical study titled "First-line Treatment of Patients With Stage IV Nonsquamous Non-Small Cell Lung Cancer With Necitumumab (IMC-11F8) and Pemetrexed-Cisplatin". The research study is testing the investigational drug necitumumab in the treatment of advanced non-small cell lung cancer. The aim of this study is to determine if necitumumab, given together with a standard chemotherapy combination consisting of cisplatin and pemetrexed will be more effective in i...
What is the current status of trial NCT00982111?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 633 participants. The study started on 2009-11-02. Estimated completion is 2020-12-23.
What interventions are being tested in trial NCT00982111?
The interventions under investigation include: Cisplatin (DRUG), Pemetrexed (DRUG), Necitumumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00982111?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.